GlassScriptPhysician profile
Steve T Linsenbardt
NPI 1972589711
$1,920.12
in general payments reported to CMS, 2019-2025
24 companies · $442 in 2025
The $442 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $104 · 2021: $190 · 2022: $389 · 2023: $240 · 2024: $407 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,089.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $433.19 | 2019-2025 | Repatha, Otezla, Prolia |
| Glaxosmithkline, LLC. | $304.71 | 2022-2025 | Shingrix, Arexvy |
| Abbott Laboratories | $144.70 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Novo Nordisk INC | $140.29 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $99.10 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $85.94 | 2022-2025 | |
| Abbvie INC. | $82.01 | 2020-2024 | |
| Esperion Therapeutics, INC. | $78.48 | 2020-2025 | Nexletol |
| Sumitomo Pharma America, INC. | $76.61 | 2024-2025 | Gemtesa |
| Ucb, INC. | $73.35 | 2024 | Cimzia |
| Merck Sharp & Dohme LLC | $69.22 | 2022-2025 | Capvaxive, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $51.57 | 2019-2021 | |
| Dexcom, INC. | $48.48 | 2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $36.98 | 2019 | |
| Janssen Biotech, INC. | $30.70 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $28.61 | 2022-2024 | Saphnelo |
| Medtronic, INC. | $26.36 | 2025 | Kyphon Express II Kyphopak Tray |
| Sunovion Pharmaceuticals INC. | $24.91 | 2022 | |
| Pharmacosmos Therapeutics INC. | $15.12 | 2024 | Monoferric |
| Lilly USA, LLC | $15.05 | 2023 | Jardiance |
| Idorsia Pharmaceuticals US INC | $14.31 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.22 | 2025 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $13.26 | 2022 | |
| Melinta Therapeutics, LLC | $12.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Linsenbardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.